QT Vascular said today that the FDA approved the company’s request to expand an on-going pivotal study of its Chocolate Touch drug-coated balloon to include the use of atherectomy for lesion preparation. The U.S. regulatory agency also approved the addition of subgroup analysis related to the use of atherectomy. Get the full story at our sister […]
QT Vascular
Teleflex to acquire QT Vascular assets, takes option on Chocolate Heart DCB
QT Vascular said today it inked a deal to sell its non-drug coated coronary products to Teleflex (NYSE:TFX), including its Chocolate XD and Glider, with an option to purchase its Chocolate Heart drug-coated coronary balloon catheter which is currently under development. Singapore-based QT Vascular has not released any financial details of the deal, but said that it will […]
Medtronic closes $28m buyout of QT Vascular’s Chocolate PTA balloon
Medtronic (NYSE:MDT) closed the $28 million acquisition of the Chocolate PTA non-drug-coated balloon made by QT Vascular, after taking an option on the device last year. In February 2017 the companies inked a 5-year deal calling for Medtronic to distribute the Chocolate PTA device. Last May the Fridley, Minn.-based medical device giant agreed to the option deal on Chocolate PTA, which […]
QT Vascular launches pivotal trial for drug-coated peripheral balloon
QT Vascular said today that it launched the U.S. pivotal trial for its Chocolate Touch drug-coated peripheral balloon in the hopes of winning FDA approval. The device won CE Mark clearance in September 2015. The trial is slated to compare the safety and effectiveness of the Chocolate Touch balloon with Bard‘s(NYSE:BCR) Lutonix drug-coated balloon catheter. The company […]
TriReme Medical touts Chocolate Heart drug-coated balloon data
QT Vascular subsidiary TriReme Medical touted angiographic data today from a 24-month follow-up of patients treated with its Chocolate Heart drug-coated balloon. The Chocolate Heart device is a paclitaxel-coated version of the company’s Chocolate coronary balloon that is commercially available in the U.S. The combo therapy was designed to reduce the incidence of repeat procedures […]
QT Vascular shops coronary assets
QT Vascular said today that it’s in discussions to sell its coronary assets, apart from the Chocolate PTA device it’s already looking to deal to Medtronic (NYSE:MDT). Earlier this month, QT Vascular said Medtronic agreed to pay $28 million for an option on the Chocolate PTA non-drug-coated balloon for treating peripheral vascular disease, after inking a 5-year […]
Medtronic options QT Vascular’s Chocolate PTA peripheral balloon
Medtronic (NYSE:MDT) agreed to acquire an option on the Chocolate PTA non-drug-coated balloon made by QT Vascular to treat peripheral vascular disease. The purchase price is $28 million, according to Singapore’s Business Times, pegged to “achievement of certain milestones,” the company said. In February the companies inked a 5-year deal calling for Medtronic to distribute the Chocolate […]
QT Vascular raises $14m
QT Vascular said this week it inked a private placement deal with Gem Global Yield Fund for up to $14.3 million (SGD $20 million) over the next 30 months. In the funding agreement, Singapore-based QT Vascular will receive up to $7.2 million (SGD $10 million) over the next 30 months, with an option for an additional […]
QT Vascular inks Chocolate PTA distro deal with Medtronic
QT Vascular said today it inked a definitive agreement with Medtronic (NYSE:MDT) to distribute QT’s Chocolate PTA catheter for 5 years. The deal between Singapore-based QT Vascular and Fridley, Minn.-based Medtronic will be automatically renewable for 2 additional 1-year periods, and both companies will continue to negotiate other aspects of their relationship. “We are honored […]
QT Vascular subsidiary TriReme lands GPO deal with HealthTrust
QT Vascular said yesterday that its TriReme Medical subsidiary inked a group purchase agreement with Healthtrust Purchasing Group. Through the newly signed deal, Healthtrust will gain access to TriReme’s portfolio of specialty angioplasty balloons designed to treat blood vessel blockage due to arterial disease, QT Vascular said. Nashville, Tenn.-based HealthTrust serves more than 1,400 acute care […]
QT Vascular wins full FDA IDE approval for Chocolate Touch DCB pivotal trial
QT Vascular said today it won full FDA investigational device exemption approval to initiate a trial of its Chocolate Touch drug-coated balloon designed to treat vascular disease. The Singapore-based company said it looks to enroll 585 patients at up to 50 US centers for the prospective, randomized trial, which aims to explore the use of the device […]